Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. Ann Hematol (2012) 0.81

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods (1995) 16.00

Active immunotherapy for acute lymphoblastic leukaemia. Lancet (1969) 13.03

Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line. J Mol Biol (1976) 7.42

Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27

Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med (1995) 4.19

Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol (2001) 2.57

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol (1989) 2.43

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43

Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome. Br J Haematol (2003) 2.36

Flow cytometry of apoptotic cell death. J Immunol Methods (2000) 2.30

Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood (2000) 2.25

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21

Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol (2001) 2.16

Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol (1989) 2.12

Aspergillus in pepper. Lancet (1989) 2.12

Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab (1995) 2.03

Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med (1992) 1.95

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92

The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood (1999) 1.87

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77

Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol (1996) 1.77

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol (2003) 1.72

Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70

Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr (2001) 1.70

Mutations in N-ras predominate in acute myeloid leukemia. Blood (1987) 1.68

Acute lymphoblastic leukaemia treated with a combination of prednisone, vincristine, and rubidomycin. Value of pathogen-free rooms. Lancet (1967) 1.65

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood (2001) 1.65

Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia (2000) 1.64

CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol (2004) 1.63

Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet (1999) 1.63

Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood (1995) 1.62

Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. J Clin Microbiol (1996) 1.61

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol (1988) 1.61

Captopril-associated agranulocytosis. Lancet (1980) 1.61

Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med (1988) 1.59

In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood (1991) 1.55

Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood (1997) 1.53

Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood (2001) 1.53

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT. Blood (2001) 1.52

Primary extranodal and nodal non-Hodgkin's lymphoma. A survey of a population-based registry. Eur J Cancer Clin Oncol (1989) 1.51

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49

Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A (1999) 1.49

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Varicella zoster virus (VZV)-related progressive outer retinal necrosis (PORN) after allogeneic stem cell transplantation. Bone Marrow Transplant (2005) 1.48

Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy. Radiother Oncol (1989) 1.48

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol (1996) 1.47

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood (2000) 1.46

Radiotherapy after ovarian transposition: ovarian function and fertility preservation. Int J Radiat Oncol Biol Phys (1993) 1.44

Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44

Acute myeloid leukemia in the elderly: biological features and search for adequate treatment. Ann Hematol (1991) 1.43

Production of tumor necrosis factor-alpha by normal and malignant B lymphocytes in response to interferon-alpha, interferon-gamma and interleukin-4. Leukemia (1992) 1.42

Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol (1999) 1.42

Diagnostic value of T-cell receptor beta gene rearrangement analysis on peripheral blood lymphocytes of patients with erythroderma. J Invest Dermatol (1991) 1.42

Stage is a better prognostic indicator than morphologic subtype in primary noncutaneous T-cell lymphoma. Am J Clin Pathol (1990) 1.41

Prolonged exposure to cytosine arabinoside in the presence of hematopoietic growth factors preferentially kills leukemic versus normal clonogenic cells. Exp Hematol (1991) 1.41

New concepts in the classification of cutaneous lymphomas. Arch Dermatol (1995) 1.41

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

Transfusion of red cells after autologous bone marrow harvest in patients with acute leukemia and malignant lymphoma. Transfusion (1990) 1.40

[Polyostotic fibrous dysplasia of the spinal column and ribs]. Dtsch Med Wochenschr (1993) 1.40

Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity. Blood (1992) 1.40

[Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]. Ned Tijdschr Geneeskd (2000) 1.39

Clinical course in 28 unselected patients with aplastic anaemia treated with anabolic steroids. Br J Haematol (1979) 1.39

UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood (2000) 1.38

Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol (2001) 1.38

Sequence analysis of the simian foamy virus type 1 genome. Gene (1991) 1.38

Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation. Mol Cell Biol (1993) 1.38

Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet (1988) 1.37

Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant (2005) 1.37

Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol (1999) 1.37

Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med (1985) 1.34

Fate of virus DNA in the abortive infection of human lymphoid cell lines by Epstein-Barr virus. J Gen Virol (1972) 1.33

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol (1998) 1.32

Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J (1970) 1.32

Characterization of a human multilineage-colony-stimulating factor cDNA clone identified by a conserved noncoding sequence in mouse interleukin-3. Gene (1987) 1.30

Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe chronic neutropenia. Blood (1998) 1.29

Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol (2000) 1.29

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia (1997) 1.28

Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol (2001) 1.28

[Demonstration of the efficacy of active immunotherapy in human acute lymphoblastic leukemia]. Rev Fr Etud Clin Biol (1968) 1.27

DFFRY codes for a new human male-specific minor transplantation antigen involved in bone marrow graft rejection. Blood (2000) 1.26

Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A (1994) 1.25

Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood (1999) 1.23

Renal complications in acute leukemias. Haematologica (1998) 1.23

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am (2000) 1.22

Clonal hematopoiesis in patients with acquired aplastic anemia. Blood (1991) 1.22

Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep (1979) 1.22

Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol (2004) 1.22

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia (2003) 1.21

Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood (1997) 1.20